Kentaro Yamamura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kentaro Yamamura has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
Megumi Aoki
Department of Dermato‐Oncology NHO Kagoshima Medical Center Kagoshima Japan
7 shared publications- Shigeto Matsushita
Department of Dermato‐Oncology NHO Kagoshima Medical Center Kagoshima Japan
6 shared publications - Teruki Dainichi
Department of Dermatology Kagawa University Faculty of Medicine Miki‐cho Kagawa Japan
3 shared publications - Yasuhiro Fujisawa
Department of Dermatology Ehime University Graduate School of Medicine Ehime Japan
3 shared publications - Yoshiyuki Nakamura
Department of Dermatology Institute of Medicine, University of Tsukuba Tsukuba Japan
3 shared publications - Jiro Uehara
Department of Dermatologic Oncology Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo Japan
2 shared publications
Latest Publications
- 17 December 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (2)
A Pediatric Case of Wells Syndrome Presenting With Recurrent Annular Erythema and Fever Successfully Treated With Baricitinib
- 17 December 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (2)
A Pediatric Case of Wells Syndrome Presenting With Recurrent Annular Erythema and Fever Successfully Treated With Baricitinib
- 2 October 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (12)
Sudden Death in a Case of Nonbullous Pemphigoid With Immunoglobulin G Anti‐120 kDa Linear IgA Bullous Dermatosis Antigen Autoantibodies
- 2 October 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (12)
Sudden Death in a Case of Nonbullous Pemphigoid With Immunoglobulin G Anti‐120 kDa Linear IgA Bullous Dermatosis Antigen Autoantibodies
- 21 July 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (9) , 1465-1469
Outcomes of Free Tarsoconjunctival Grafts in Lower Eyelid Reconstruction Following Basal Cell Carcinoma Surgery
The treatment of skin malignancies of the lower eyelid presents unique challenges due to the thin skin, proximity to vital structures, and the functional importance of the eyelid. Although surgical excision remains the standard approach for such malignancies, lower eyelid reconstruction is critical for preserving both function and aesthetics. Free tarsoconjunctival grafts (FTGs) have emerged as effective options for posterior lamellar reconstruction, providing structural support and long‐term stability. This retrospective study analyzed cases of lower eyelid reconstruction using FTGs between December 2014 and November 2024. Eleven cases met the inclusion criteria, all of which involved basal cell carcinoma (BCC). During this period, 115 lower eyelid BCC cases were treated, and FTGs were selectively applied in 9.6% of cases. Grafts were harvested from the ipsilateral upper eyelid, with dimensions ranging from 5 to 11 mm in width and 3 to 5 mm in height. Postoperative outcomes, including complications, graft dimensions, and tumor recurrence, were evaluated. No major complications were observed. Minor complications occurred in three cases: one patient developed trichiasis at the graft site, and two patients experienced mild corneal epithelial damage. However, none of the patients reported subjective symptoms related to these complications. At a mean follow‐up of 19.3 months, no tumor recurrence was observed, although one patient died of unrelated causes. These findings highlight the suitability of FTGs for small to moderately sized defects. Careful graft size selection leads to favorable outcomes with minimal complications. Overall, FTGs are a reliable and safe option for lower eyelid reconstruction, balancing oncological safety, functional preservation, and aesthetic outcomes in conservative surgical approaches for BCC treatment.
- 21 July 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (9) , 1465-1469
Outcomes of Free Tarsoconjunctival Grafts in Lower Eyelid Reconstruction Following Basal Cell Carcinoma Surgery
The treatment of skin malignancies of the lower eyelid presents unique challenges due to the thin skin, proximity to vital structures, and the functional importance of the eyelid. Although surgical excision remains the standard approach for such malignancies, lower eyelid reconstruction is critical for preserving both function and aesthetics. Free tarsoconjunctival grafts (FTGs) have emerged as effective options for posterior lamellar reconstruction, providing structural support and long‐term stability. This retrospective study analyzed cases of lower eyelid reconstruction using FTGs between December 2014 and November 2024. Eleven cases met the inclusion criteria, all of which involved basal cell carcinoma (BCC). During this period, 115 lower eyelid BCC cases were treated, and FTGs were selectively applied in 9.6% of cases. Grafts were harvested from the ipsilateral upper eyelid, with dimensions ranging from 5 to 11 mm in width and 3 to 5 mm in height. Postoperative outcomes, including complications, graft dimensions, and tumor recurrence, were evaluated. No major complications were observed. Minor complications occurred in three cases: one patient developed trichiasis at the graft site, and two patients experienced mild corneal epithelial damage. However, none of the patients reported subjective symptoms related to these complications. At a mean follow‐up of 19.3 months, no tumor recurrence was observed, although one patient died of unrelated causes. These findings highlight the suitability of FTGs for small to moderately sized defects. Careful graft size selection leads to favorable outcomes with minimal complications. Overall, FTGs are a reliable and safe option for lower eyelid reconstruction, balancing oncological safety, functional preservation, and aesthetic outcomes in conservative surgical approaches for BCC treatment.
- 27 December 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (1) , 183-186
Age over 90 years is an unfavorable prognostic factor for resectable cutaneous squamous cell carcinoma
The rapid aging of the population has led to an increase in the number of cutaneous squamous cell carcinoma (cSCC) cases among the older population. However, the characteristics of these cases remain unclear. In this study, we aimed to identify the problem by analyzing the clinical characteristics of patients with cSCC aged 90 years and over. In this retrospective study, we analyzed the characteristics of patients aged >90 years with regard to gender, risk factors for cSCC, and disease course, using data from 316 patients with cSCC who underwent surgery at the Kagoshima Medical Centre between October 2014 and September 2022. Patients were separated into two groups based on age: those aged ≥90 years (104 patients) and those aged <90 years (212 patients). Regarding the National Comprehensive Cancer Network risk classification, there was no difference between groups. Univariate, multivariate, and Cox analyses of relapse‐free survival of patients in both groups indicated that the recurrence risk was significantly high among those aged ≥90 years. Patients aged ≥90 years were at higher risk for recurrence, suggesting a need for closer follow‐up than that for patients aged <90 years.
- 27 December 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (1) , 183-186
Age over 90 years is an unfavorable prognostic factor for resectable cutaneous squamous cell carcinoma
The rapid aging of the population has led to an increase in the number of cutaneous squamous cell carcinoma (cSCC) cases among the older population. However, the characteristics of these cases remain unclear. In this study, we aimed to identify the problem by analyzing the clinical characteristics of patients with cSCC aged 90 years and over. In this retrospective study, we analyzed the characteristics of patients aged >90 years with regard to gender, risk factors for cSCC, and disease course, using data from 316 patients with cSCC who underwent surgery at the Kagoshima Medical Centre between October 2014 and September 2022. Patients were separated into two groups based on age: those aged ≥90 years (104 patients) and those aged <90 years (212 patients). Regarding the National Comprehensive Cancer Network risk classification, there was no difference between groups. Univariate, multivariate, and Cox analyses of relapse‐free survival of patients in both groups indicated that the recurrence risk was significantly high among those aged ≥90 years. Patients aged ≥90 years were at higher risk for recurrence, suggesting a need for closer follow‐up than that for patients aged <90 years.
- 11 October 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 50 (1) , E28-E29
BRAF N581S and NRAS Q61R ‐mutated malignant melanoma and sensitivity to BRAF / MEK inhibitors
- 11 October 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 50 (1) , E28-E29
BRAF N581S and NRAS Q61R ‐mutated malignant melanoma and sensitivity to BRAF / MEK inhibitors
- 5 May 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 49 (9) , 837-844
Concordance in judgment of clinical borders of basal cell carcinomas in Japanese patients: A preliminary study of JCOG2005 (J‐BASE‐MARGIN)
Basal cell carcinoma is the most common type of skin cancer, and surgical excision with clear margins is the standard of care. Surgical margins are determined based on risk factors (high or low risk) for recurrence according to the National Comprehensive Cancer Network and Japanese basal cell carcinoma guidelines. The clarity of the clinical tumor border (well-defined or poorly defined) is considered a risk factor, and significant discrepancies in the judgment of clinical tumor borders among dermato-oncologists may occur. Therefore, we analyzed the dermato-oncologists' concordance in judging the clinical tumor border of basal cell carcinoma. Forty-seven dermato-oncologists (experts: 37; young trainees: 10) participated in this study. The datasets of clinical and dermoscopic photographs of 79 Japanese cases of head and neck basal cell carcinoma were used to determine the concordance in the judgment of clinical tumor border. The probability of the border that was selected more often was used to calculate the rater agreement rate for each dataset. Correct judgment was defined as a more frequently selected border, and the concordance rate of clarity of clinical tumor border for each dermato-oncologist was calculated based on the definition of the correct judgment. A median concordance rate of 85% or higher for all dermato-oncologists was predefined as an acceptable rate for clinical use. Of the 79 datasets, rater agreement rates were 80-100%, 60-79%, and 51-59% for 55, 19, and five datasets, respectively. The median concordance rate for all dermato-oncologists was 86% (interquartile range: 82-89%). There was no significant difference in the concordance rate between the experts and the trainees (median, 87% vs. 85.5%; p = 0.58). The concordance rates of dermato-oncologists for all datasets were relatively high and acceptable for clinical use.
- 5 May 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 49 (9) , 837-844
Concordance in judgment of clinical borders of basal cell carcinomas in Japanese patients: A preliminary study of JCOG2005 (J‐BASE‐MARGIN)
Basal cell carcinoma is the most common type of skin cancer, and surgical excision with clear margins is the standard of care. Surgical margins are determined based on risk factors (high or low risk) for recurrence according to the National Comprehensive Cancer Network and Japanese basal cell carcinoma guidelines. The clarity of the clinical tumor border (well-defined or poorly defined) is considered a risk factor, and significant discrepancies in the judgment of clinical tumor borders among dermato-oncologists may occur. Therefore, we analyzed the dermato-oncologists' concordance in judging the clinical tumor border of basal cell carcinoma. Forty-seven dermato-oncologists (experts: 37; young trainees: 10) participated in this study. The datasets of clinical and dermoscopic photographs of 79 Japanese cases of head and neck basal cell carcinoma were used to determine the concordance in the judgment of clinical tumor border. The probability of the border that was selected more often was used to calculate the rater agreement rate for each dataset. Correct judgment was defined as a more frequently selected border, and the concordance rate of clarity of clinical tumor border for each dermato-oncologist was calculated based on the definition of the correct judgment. A median concordance rate of 85% or higher for all dermato-oncologists was predefined as an acceptable rate for clinical use. Of the 79 datasets, rater agreement rates were 80-100%, 60-79%, and 51-59% for 55, 19, and five datasets, respectively. The median concordance rate for all dermato-oncologists was 86% (interquartile range: 82-89%). There was no significant difference in the concordance rate between the experts and the trainees (median, 87% vs. 85.5%; p = 0.58). The concordance rates of dermato-oncologists for all datasets were relatively high and acceptable for clinical use.
- 24 July 2021
- Published by Wiley in The Journal of Dermatology
- Vol. 48 (10) , E520-E521
Anorectal function preserving surgery with endoscopic submucosal dissection in patients with perianal extramammary Paget’s disease
- 24 July 2021
- Published by Wiley in The Journal of Dermatology
- Vol. 48 (10) , E520-E521
Anorectal function preserving surgery with endoscopic submucosal dissection in patients with perianal extramammary Paget’s disease
- 1 January 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (1) , E59-E61
Atypical blue naevus of the labium minus confirmed by whole-exome sequencing
Blue nevus is a subset of benign melanocytic tumors typically located on the dorsal aspects of extremities, scalp, and buttocks. It is also reported to occur rarely even at the oral and genital mucosa. Herein, we report a case of blue nevus of the labium minus with atypical clinical manifestations, which was confirmed by whole‐exome sequencing.
- 1 January 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (1) , E59-E61
Atypical blue naevus of the labium minus confirmed by whole-exome sequencing
Blue nevus is a subset of benign melanocytic tumors typically located on the dorsal aspects of extremities, scalp, and buttocks. It is also reported to occur rarely even at the oral and genital mucosa. Herein, we report a case of blue nevus of the labium minus with atypical clinical manifestations, which was confirmed by whole‐exome sequencing.
- 10 April 2020
- Published by Wiley in The Journal of Dermatology
- Vol. 47 (6) , 629-635
Vitiligo expansion and extent correlate with durable response in anti‐programmed death 1 antibody treatment for advanced melanoma: A multi‐institutional retrospective study
Vitiligo is an autoimmune disorder resulting from the destruction of melanocytes. Several reports indicate the association between vitiligo and treatment response in advanced melanoma during immunotherapy. It has not been investigated, however, if an increase of vitiligo while on treatment with anti‐programmed death 1 (PD‐1) antibodies is associated with more durable responses. The aim of this study is to evaluate the correlation between the vitiligo dynamics and clinical efficacy of anti‐PD‐1 antibodies. This study included advanced melanoma patients who were treated with nivolumab or pembrolizumab and developed vitiligo thereafter. Correlation between vitiligo expansion (defined as an increase of lesion size at two separate time points at least 4 weeks apart) as well as vitiligo extent (body surface area [BSA] affected) and clinical efficacy based on response rate, progression‐free survival and overall survival was assessed. We retrospectively reviewed 29 patients. The median time from the initiation of anti‐PD‐1 antibody to vitiligo onset was 4.3 months in patients who showed a response and 5.5 months in patients who showed no response (P = 0.31). Twelve patients showed vitiligo expansion, and in nine of these patients, vitiligo increased to grade 2 (covering ≥ 10% BSA). Vitiligo expansion and grade 2 vitiligo showed no improvement in treatment response (P = 0.59 and 0.25) but were associated with prolonged progression‐free survival (P = 0.019 and 0.04). Grade 2 vitiligo also showed a trend for prolonged overall survival (P = 0.07). Trend of expansion and larger vitiligo extent may be predictive factors of prolonged survival during anti‐PD‐1 antibody in melanoma patients.
- 10 April 2020
- Published by Wiley in The Journal of Dermatology
- Vol. 47 (6) , 629-635
Vitiligo expansion and extent correlate with durable response in anti‐programmed death 1 antibody treatment for advanced melanoma: A multi‐institutional retrospective study
Vitiligo is an autoimmune disorder resulting from the destruction of melanocytes. Several reports indicate the association between vitiligo and treatment response in advanced melanoma during immunotherapy. It has not been investigated, however, if an increase of vitiligo while on treatment with anti‐programmed death 1 (PD‐1) antibodies is associated with more durable responses. The aim of this study is to evaluate the correlation between the vitiligo dynamics and clinical efficacy of anti‐PD‐1 antibodies. This study included advanced melanoma patients who were treated with nivolumab or pembrolizumab and developed vitiligo thereafter. Correlation between vitiligo expansion (defined as an increase of lesion size at two separate time points at least 4 weeks apart) as well as vitiligo extent (body surface area [BSA] affected) and clinical efficacy based on response rate, progression‐free survival and overall survival was assessed. We retrospectively reviewed 29 patients. The median time from the initiation of anti‐PD‐1 antibody to vitiligo onset was 4.3 months in patients who showed a response and 5.5 months in patients who showed no response (P = 0.31). Twelve patients showed vitiligo expansion, and in nine of these patients, vitiligo increased to grade 2 (covering ≥ 10% BSA). Vitiligo expansion and grade 2 vitiligo showed no improvement in treatment response (P = 0.59 and 0.25) but were associated with prolonged progression‐free survival (P = 0.019 and 0.04). Grade 2 vitiligo also showed a trend for prolonged overall survival (P = 0.07). Trend of expansion and larger vitiligo extent may be predictive factors of prolonged survival during anti‐PD‐1 antibody in melanoma patients.